<VariationArchive VariationID="2758939" VariationName="NM_000709.4(BCKDHA):c.1237dup (p.Tyr413fs)" VariationType="Duplication" Accession="VCV002758939" Version="1" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-04-06" DateCreated="2024-02-14" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2921410" VariationID="2758939">
      <GeneList>
        <Gene Symbol="BCKDHA" FullName="branched chain keto acid dehydrogenase E1 subunit alpha" GeneID="593" HGNC_ID="HGNC:986" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>19q13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="41397818" stop="41425002" display_start="41397818" display_stop="41425002" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="41903693" stop="41930909" display_start="41903693" display_stop="41930909" Strand="+" />
          </Location>
          <OMIM>608348</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000709.4(BCKDHA):c.1237dup (p.Tyr413fs)</Name>
      <CanonicalSPDI>NC_000019.10:41424506:T:TT</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>19q13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="41424506" stop="41424507" display_start="41424506" display_stop="41424507" variantLength="1" positionVCF="41424506" referenceAlleleVCF="G" alternateAlleleVCF="GT" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="41930411" stop="41930412" display_start="41930411" display_stop="41930412" variantLength="1" positionVCF="41930411" referenceAlleleVCF="G" alternateAlleleVCF="GT" />
      </Location>
      <ProteinChange>Y412fs</ProteinChange>
      <ProteinChange>Y413fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.10" sequenceAccession="NC_000019" sequenceVersion="10" change="g.41424507dup" Assembly="GRCh38">
            <Expression>NC_000019.10:g.41424507dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.9" sequenceAccession="NC_000019" sequenceVersion="9" change="g.41930412dup" Assembly="GRCh37">
            <Expression>NC_000019.9:g.41930412dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_013004.1" sequenceAccession="NG_013004" sequenceVersion="1" change="g.31719dup">
            <Expression>NG_013004.1:g.31719dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000709.4" sequenceAccession="NM_000709" sequenceVersion="4" change="c.1237dup" MANESelect="true">
            <Expression>NM_000709.4:c.1237dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000700.1" sequenceAccession="NP_000700" sequenceVersion="1" change="p.Tyr413fs">
            <Expression>NP_000700.1:p.Tyr413fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001164783.2" sequenceAccession="NM_001164783" sequenceVersion="2" change="c.1234dup">
            <Expression>NM_001164783.2:c.1234dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001158255.1" sequenceAccession="NP_001158255" sequenceVersion="1" change="p.Tyr412fs">
            <Expression>NP_001158255.1:p.Tyr412fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000709.4(BCKDHA):c.1237dup (p.Tyr413fs) AND Maple syrup urine disease" Accession="RCV003524677" Version="1">
        <ClassifiedConditionList TraitSetID="6467">
          <ClassifiedCondition DB="MedGen" ID="C0024776">Maple syrup urine disease</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-10-17" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-10-17" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2024-02-14" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">11825067</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12888983</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">2703538</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">28170084</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="6467" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2822" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Maple syrup urine disease</ElementValue>
                <XRef ID="Maple+syrup+urine+disease/4453" DB="Genetic Alliance" />
                <XRef ID="MONDO:0009563" DB="MONDO" />
                <XRef Type="Phenotypic series" ID="PS248600" DB="OMIM" />
                <XRef ID="511" DB="Orphanet" />
                <XRef ID="27718001" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MSUD</ElementValue>
                <XRef Type="MIM" ID="248600" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Maple syrup urine disease (MSUD) is categorized as classic (severe), intermediate, or intermittent. Neonates with classic MSUD are born asymptomatic but without treatment follow a predictable course: 12â€“24 hours. Elevated concentrations of branched-chain amino acids (BCAAs; leucine, isoleucine, and valine) and alloisoleucine, as well as a generalized disturbance of amino acid concentration ratios, are present in blood and the maple syrup odor can be detected in cerumen; Two to three days. Early and nonspecific signs of metabolic intoxication (i.e., irritability, hypersomnolence, anorexia) are accompanied by the presence of branched-chain alpha-ketoacids, acetoacetate, and beta-hydroxybutyrate in urine; Four to six days. Worsening encephalopathy manifests as lethargy, apnea, opisthotonos, and reflexive "fencing" or "bicycling" movements as the sweet maple syrup odor becomes apparent in urine; Seven to ten days. Severe intoxication culminates in critical cerebral edema, coma, and central respiratory failure. Individuals with intermediate MSUD have partial branched-chain alpha-ketoacid dehydrogenase deficiency that manifests only intermittently or responds to dietary thiamine therapy; these individuals can experience severe metabolic intoxication and encephalopathy in the face of sufficient catabolic stress. In the era of newborn screening (NBS), the prompt initiation of treatment of asymptomatic infants detected by NBS means that most individuals who would have developed neonatal manifestations of MSUD remain asymptomatic with continued treatment compliance.</Attribute>
                <XRef ID="NBK1319" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000519087" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570054" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528449" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528448" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521391" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522527" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000505096" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000529111" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592960" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591289" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000505125" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522317" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000561777" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3228" />
                <XRef ID="3228" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301495</ID>
                <ID Source="BookShelf">NBK1319</ID>
              </Citation>
              <Citation Type="general" Abbrev="GMDI/SERC, 2014">
                <ID Source="PubMed">24881969</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2011">
                <URL>http://www.acmg.net/ACMG/UploadedPDFS/PDFDocuments/Carrier-Screening-ACT-SheetAshkenazi-Jewish-Genetic-Disorders.aspx</URL>
                <CitationText>American College of Medical Genetics ACT Sheet, Carrier Screening ACT Sheet Ashkenazi Jewish Genetic Disorders</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="GMDI/SERN, 2021">
                <URL>https://managementguidelines.net/guidelines.php/129/MSUD%20Nutrition%20Guidelines/Version%201.58</URL>
                <CitationText>MSUD Nutrition Management Guidelines</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2021">
                <URL>https://www.acmg.net/PDFLibrary/Leucine.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Increased Leucine, Maple Syrup Urine Disease, 2021</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2021">
                <URL>https://www.acmg.net/PDFLibrary/Leucine-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Leucine Elevated, 2021</CitationText>
              </Citation>
              <XRef ID="511" DB="Orphanet" />
              <XRef ID="C0024776" DB="MedGen" />
              <XRef ID="D008375" DB="MeSH" />
              <XRef ID="MONDO:0009563" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS248600" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="8008449" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2024-02-14">
        <ClinVarSubmissionID localKey="27450288|MedGen:C0024776" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004323808" DateUpdated="2024-02-14" DateCreated="2024-02-14" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-10-17">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">2703538</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11825067</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12888983</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28170084</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Tyr413Leufs*33) in the BCKDHA gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 33 amino acid(s) of the BCKDHA protein. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with BCKDHA-related conditions. This variant disrupts a region of the BCKDHA protein in which other variant(s) (p.Tyr438Asn) have been determined to be pathogenic (PMID: 2703538, 11825067, 12888983, 28170084). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BCKDHA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000019.9:g.41930411_41930412insT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0024776" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14200283</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="8008449" TraitType="Disease" MappingType="XRef" MappingValue="C0024776" MappingRef="MedGen">
        <MedGen CUI="C0024776" Name="Maple syrup urine disease" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

